The future is now for precision genomiaddiction medicine as a frontline modality for inducing dopamine homeostasis in reward deficiency syndrome

In this genomic era of addiction medicine, ideal treatment planning begins with genetic screening to determine neurogenetic antecedents of Reward Deficiency Syndrome (RDS) phenotype. Patients suffering from endotype addictions and mental disorders share the common underlying neurobiology of dopamine dysfunction.

Audience Take Away:

• The audience will learn about the advancements in molecular biology which have changed the addiction recovery landscape.
• The audience will learn how to distinguish genetics from genomics, and be taught why these are important to addiction medicine, behavioral health and psychology.
• Practitioners will receive a brief introduction to Reward Deficiency Syndrome psychoeducation, which is continuing education in genomic medicine.
• Case study research of the effectiveness of Precision Genomic Addiction Medicine, as compared to traditional treatment is well received.